We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Studies Show Geron’s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors
News

Studies Show Geron’s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors

Studies Show Geron’s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors
News

Studies Show Geron’s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Studies Show Geron’s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Geron Corporation has reported that studies show GRNOPC1, the company’s human embryonic stem cell (hESC)-based oligodendroglial progenitor therapeutic, produces multiple nerve growth factors, proteins that stimulate the survival and regeneration of neurons damaged during spinal cord injury.

Published in Stem Cells and Development, the studies conducted by Geron scientists describe a newly discovered neurotrophic effect that, in addition to the previously documented in vivo remyelinating activity of these cells, serves as a second mechanism of action that demonstrates the product’s beneficial effects when injected into animal models of acute spinal cord injury.

“The work extends our knowledge of the multiple biological activities of GRNOPC1,” stated Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer.

“In addition to the remyelinating activity as previously reported, GRNOPC1 produces growth factors that can improve the survival and extension of neuronal circuitry in the spinal cord. The multiple functions of GRNOPC1 affirm the potential therapeutic utility of our cell-based approach to the repair of spinal cord injury and provide multiple mechanisms within a single therapy to achieve functional recovery.”

In the published studies, GRNOPC1 was found to produce numerous neurotrophic factors, including transforming growth factor ß1 (TGF-ß1), transforming growth factor ß2 (TGF-ß2), activin A, midkine, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). These factors were all produced at physiologically active levels, and each has been reported to have trophic effects on neurons associated with the spinal cord.

The studies also demonstrate that neurotrophic factors produced by GRNOPC1 are biologically active. When culture medium used to grow GRNOPC1 was applied to adult rat sensory neurons, sprouts called neurites emerged from the rat neurons. Media that had not been exposed to GRNOPC1 stimulated significantly less neurite outgrowth.

“Our studies show that multiple neurotrophic factors are produced by GRNOPC1 that lead to neurite outgrowth,” said R. Scott Thies, Ph.D., Geron’s lead investigator on the work.

“Depletion or inactivation of any single factor did not eliminate the neurotrophic activity exhibited by these cells.”

Advertisement